Most labs want to use AI, but few have the digital foundations to support it. Cenevo’s leaders explain why progress is slow and what laboratories must fix before AI can deliver real value.

This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.

Insilico Medicine and Liquid AI have partnered to develop a lightweight artificial intelligence foundation model designed to support multiple stages of drug discovery.

Flare Therapeutics has selected Simplicis Ledger™ as its primary compound and inventory management platform, marking a strategic move toward a more resilient and automated approach to drug discovery.

ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its board, bringing extensive expertise to lead scientific programmes and early career initiatives.

Japanese researchers have shown in a rat study that stem cells derived from naturally shed baby teeth may improve motor and cognitive impairments in chronic-phase cerebral palsy.

Ohio University researchers have discovered that blocking the growth hormone receptor could make lung cancer treatments more effective, offering potential new treatments for patients with therapy-resistant tumours.

Scientists at Arizona State University have discovered that the way nanoparticles interact with water determines how they behave inside the human body, providing a new thermodynamic framework that could lead to more effective nanomedicines.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.